Drug Resistance Among Asymptomatic Infection
Study Details
Study Description
Brief Summary
A cross-sectional study will be conducted in selected 2 sentinel sites for assessment of drug resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Although malaria prevalence is decreasing in Myanmar, drug resistance threatens the malaria elimination by 2030 especially high risk persons including migrant population. Previous study indicated that asymptomatic malaria parasite carried drug resistance gene such as K13 mutant that is genetically responsible for artemisinin resistant falciparum malaria. These asymptomatic carries may be a source to spread the disease and it is very important to conduct the surveillance on drug resistance status among high vulnerable persons. Unfortunately, there is no study to assess the drug resistance molecular markers in asymptomatic malaria among migrant workers in Myanmar. Therefore, this study fulfills the gaps of knowledge on important of asymptomatic hidden infection exploring to formulate the recommendation for elimination of malaria in Myanmar.
In this study, asymptomatic infections are screened by rapid diagnostic test, microscopy and molecular methods.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Shwegyin Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared. |
Genetic: Drug resistance molecular markers
Proportion of the drug resistance molecular markers will be found-out and compared.
|
| Pinlebu Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared. |
Genetic: Drug resistance molecular markers
Proportion of the drug resistance molecular markers will be found-out and compared.
|
Outcome Measures
Primary Outcome Measures
- Prevalence of the asymptomatic infection among the study population [1 week]
Number of the hidden malaria cases by RDT, microscopy or nested PCR (molecular method)
- Proportion of the drug resistance molecular markers among asymptomatic infections [3 months]
Among the asymptomatic cases, molecular markers will be analyzed (K13 and pfmdr1 copy number for falciparum and pvcrt-o, pvmdr1, pvdhps and pvdhfr gene analysis for vivax cases by Sanger Sequencing.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age above 6 year
-
Migrant population (moving from their normal residence place and working at a new place such as forest related activities, gold-mines or plantation sites for more than 3 months- 3 years)
-
Both sex
-
Participant who give informed-consent to participate the study
Exclusion Criteria:
-
Known clinical malaria cases regardless of the species detected
-
Patients with clinical symptoms of malaria at the time of examination
-
Known history of malaria within 14 days
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Dr. Myat Phone Kyaw | Yangon | Myanmar | 11191 |
Sponsors and Collaborators
- Department of Medical Research, Lower Myanmar
- National Malaria Control Program, Myanmar
Investigators
- Principal Investigator: Myat H Nyunt, PhD, Department of Medical Research
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DMR_2018-108